Curis Lifesciences Ltd

Curis Lifescien. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Curis Lifesciences Ltd

₹ 118 5.54%
15 Dec - close price
curisls.com NSE - SME: CURIS
About

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]

Key Points

Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.

Website NSE - SM
  • Market Cap ₹ 95.6 Cr.
  • Current Price ₹ 118
  • High / Low ₹ 148 / 107
  • Stock P/E 11.7
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 34.2 %
  • ROE 55.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 86.3 to 55.9 days.

Cons

  • Promoter holding has decreased over last quarter: -24.6%
  • Company might be capitalizing the interest cost
  • Working capital days have increased from 38.4 days to 99.6 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2024 Mar 2025 Sep 2025
15.90 34.36 27.91
12.09 27.43 21.92
Operating Profit 3.81 6.93 5.99
OPM % 23.96% 20.17% 21.46%
-0.02 0.05 0.00
Interest 0.50 0.61 0.43
Depreciation 0.34 0.34 0.34
Profit before tax 2.95 6.03 5.22
Tax % 25.42% 33.67% 19.35%
2.20 4.00 4.21
EPS in Rs 44.00 6.74 7.09
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
23.70 35.21 35.13 49.13 62.27
20.12 31.95 26.74 39.59 49.35
Operating Profit 3.58 3.26 8.39 9.54 12.92
OPM % 15.11% 9.26% 23.88% 19.42% 20.75%
0.02 0.34 0.31 0.51 0.05
Interest 1.62 1.33 0.85 1.11 1.04
Depreciation 0.75 0.73 0.68 0.67 0.68
Profit before tax 1.23 1.54 7.17 8.27 11.25
Tax % 59.35% 20.13% 32.22% 26.24%
0.49 1.23 4.87 6.11 8.21
EPS in Rs 9.80 24.60 97.40 10.30 13.83
Dividend Payout % 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 28%
TTM: 40%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 132%
TTM: 25%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 55%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 0.50 0.50 0.50 5.93 5.93
Reserves -1.40 -0.18 5.37 10.29 14.49
17.62 16.19 17.09 15.61 14.81
10.68 13.16 10.91 10.70 14.16
Total Liabilities 27.40 29.67 33.87 42.53 49.39
12.33 12.20 11.59 10.99 10.78
CWIP 0.00 0.00 0.00 0.02 0.02
Investments 0.01 0.01 0.01 0.01 0.01
15.06 17.46 22.27 31.51 38.58
Total Assets 27.40 29.67 33.87 42.53 49.39

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025
4.95 3.35 0.28 -1.76
-0.37 -0.55 -0.06 -0.02
-4.58 -2.76 0.05 1.67
Net Cash Flow -0.01 0.04 0.27 -0.11

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 96.10 98.17 104.94 55.87
Inventory Days 208.46 114.92 273.22 347.26
Days Payable 359.58 262.67 210.40 112.29
Cash Conversion Cycle -55.01 -49.58 167.75 290.83
Working Capital Days -16.02 -20.84 36.26 99.63
ROCE % 17.21% 40.64% 34.24%

Shareholding Pattern

Numbers in percentages

4 Recently
Nov 2025
68.03%
2.93%
10.86%
18.17%
No. of Shareholders 542

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.